Furosemide |
0.8 (Bard et al., 2004) |
96–98 (Prandota and Pruitt, 1975) |
OAT3a (Hasannejad et al., 2004) |
|
|
|
MRP4b (Hasegawa et al., 2007) |
Bumetanide |
0.04 (Bard et al., 2004) |
95 (Pentikainen et al., 1985) |
OAT3a (Hasannejad et al., 2004) |
|
|
|
OAT4b (Hasannejad et al., 2004) |
Torasemide |
0.5 (Bard et al., 2004) |
99 (Knauf and Mutschler, 1998) |
OAT4b (Vormfelde et al., 2006) |
Chlorothiazide |
0.3 (Welling and Barbhaiya, 1982) |
70 (Shah et al., 1984) |
OAT1a (Hasannejad et al., 2004) |
Hydrochlorothiazide |
0.1 (Weir et al., 1998) |
40–60 (Friedman, 1988) |
OAT1a (Hasannejad et al., 2004) |
|
|
|
MRP4b (Hasegawa et al., 2007) |
Salicylate |
351 (Keystone et al., 1982) |
58 (Dollery, 1991b) |
OAT1a (Apiwattanakul et al., 1999), 2a and 3a (Khamdang et al., 2002) |
|
|
|
OAT4b (Khamdang et al., 2002), URAT1b (Anzai et al., 2007) |
Sulfinpyrazone |
7 (Dieterle et al., 1975) |
98–99 (Perel et al., 1964) |
— |
Benzbromarone |
0.8 (Ferber et al., 1981) |
99 (Walter-Sack et al., 1988) |
— |
Probenecid |
42 (Selen et al., 1982) |
90 (Dayton et al., 1963) |
— |
Allopurinol |
9 (Turnheim et al., 1999) |
<5 (Dollery, 1991a) |
OAT2a (Kobayashi et al., 2005) |
Oxypurinol |
25 (Turnheim et al., 1999) |
17 (Dollery, 1991a) |
URAT1b (Iwanaga et al., 2005) |